1,317 results on '"Grossman, H. Barton"'
Search Results
2. PD48-07 PIVOTAL STUDY EVALUATING PERFORMANCE OF BLADDER EPICHECK, AN FDA CLEARED TEST, IN NON-MUSCLE INVASIVE BLADDER CANCER
3. Can Biomarkers Guide the Use of Neoadjuvant Chemotherapy in T2 Bladder Cancer?
4. Dysregulation of EMT Drives the Progression to Clinically Aggressive Sarcomatoid Bladder Cancer
5. Using Grade of Recurrent Tumor to Guide Further Therapy While on Bacillus Calmette-Guerin: Low-grade Recurrences Are not Benign
6. Whole-Organ Genomic Characterization of Mucosal Field Effects Initiating Bladder Carcinogenesis
7. Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy
8. Is folic acid safe for non–muscle-invasive bladder cancer patients? An evidence-based cohort study
9. Epidemiology, prevention, screening, diagnosis, and evaluation: update of the ICUD–SIU joint consultation on bladder cancer
10. Papillary Recurrence of Bladder Cancer at First Evaluation after Induction Bacillus Calmette-Guérin Therapy: Implication for Clinical Trial Design
11. Microhematuria assessment an IBCN consensus—Based upon a critical review of current guidelines
12. Data from A Randomized Controlled Trial of Celecoxib to Prevent Recurrence of Nonmuscle-Invasive Bladder Cancer
13. Perspective on This Article from A Randomized Controlled Trial of Celecoxib to Prevent Recurrence of Nonmuscle-Invasive Bladder Cancer
14. Data from Effects of mTOR Inhibitor Everolimus (RAD001) on Bladder Cancer Cells
15. Supplementary Figures S1-S3 from Effects of mTOR Inhibitor Everolimus (RAD001) on Bladder Cancer Cells
16. Data from The 19q12 Bladder Cancer GWAS Signal: Association with Cyclin E Function and Aggressive Disease
17. Supplementary Materials, Figures 1 - 3, Tables 1 - 4, 6 - 8 from The 19q12 Bladder Cancer GWAS Signal: Association with Cyclin E Function and Aggressive Disease
18. Supplementary Table 5 from The 19q12 Bladder Cancer GWAS Signal: Association with Cyclin E Function and Aggressive Disease
19. Clinical Outcomes of cT1 Micropapillary Bladder Cancer
20. Intravesical Tumor Involvement of the Trigone Is Associated With Nodal Metastasis in Patients Undergoing Radical Cystectomy
21. Considerations on the use of urine markers in the management of patients with low-/intermediate-risk non–muscle invasive bladder cancer
22. Fluorescence Cytoscopy
23. Safety of Hexaminolevulinate for Blue Light Cystoscopy in Bladder Cancer. A Combined Analysis of the Trials Used for Registration and Postmarketing Data
24. Anterior Fascial Fixation Does Not Reduce the Parastomal Hernia Rate After Radical Cystectomy and Ileal Conduit
25. Refining Patient Selection for Neoadjuvant Chemotherapy before Radical Cystectomy
26. Phase 1b Trial to Evaluate Tissue Response to a Second Dose of Intravesical Recombinant Adenoviral Interferon α2b Formulated in Syn3 for Failures of Bacillus Calmette–Guerin (BCG) Therapy in Nonmuscle Invasive Bladder Cancer
27. Bladder Cancer : Clinical Strategies for Cancer Chemoprevention
28. Phase I Trial of Intravesical Recombinant Adenovirus Mediated Interferon-α2b Formulated in Syn3 for Bacillus Calmette-Guérin Failures in Nonmuscle Invasive Bladder Cancer
29. Recent Developments in the Treatment of Bladder Cancer
30. Tumor Suppressor Genes of Bladder Cancer and Potential for Gene Therapy
31. The Use of Tumor Markers in Bladder Cancer and Current Concepts on Clinical Applicability
32. The role of FISH and cytology in upper urinary tract surveillance after radical cystectomy for bladder cancer
33. Long-Term Decrease in Bladder Cancer Recurrence with Hexaminolevulinate Enabled Fluorescence Cystoscopy
34. Use of Fluorescence In Situ Hybridization to Predict Response to Bacillus Calmette-Guérin Therapy for Bladder Cancer: Results of a Prospective Trial
35. All High-Grade Ta Tumors Should Be Classified as High Risk: Bacillus Calmette-Guérin Response in High-Grade Ta Tumors
36. Reply by Authors
37. Urothelial Differentiation and Bladder Cancer
38. Plasma Vitamins E and A and Risk of Bladder Cancer: A Case-Control Analysis
39. The role of radical cystectomy in patients with clinical T4b bladder cancer
40. Perioperative Outcomes of Laparoscopic Radical Nephroureterectomy and Regional Lymphadenectomy in Patients With Upper Urinary Tract Urothelial Carcinoma After Neoadjuvant Chemotherapy
41. Robot Assisted Extended Pelvic Lymphadenectomy at Radical Cystectomy: Lymph Node Yield Compared With Second Look Open Dissection
42. Urinary Tract Diseases and Bladder Cancer Risk: A Case-Control Study
43. MP59-01 URINE MICRORNAS AS LIQUID BIOPSY ASSAY FOR PREDICTING RESPONSE TO INTRAVESICAL BCG THERAPY
44. Considerations on implementing diagnostic markers into clinical decision making in bladder cancer
45. BCAN Think Tank session 3: Prevention of bladder cancer
46. Age and Body Mass Index Are Independent Risk Factors for the Development of Postoperative Paralytic Ileus After Radical Cystectomy
47. Hexaminolevulinate Guided Fluorescence Cystoscopy Reduces Recurrence in Patients With Nonmuscle Invasive Bladder Cancer
48. Risk Factor Analysis in a Contemporary Cystectomy Cohort Using Standardized Reporting Methodology and Adverse Event Criteria
49. Loss of 15-Hydroxyprostaglandin Dehydrogenase Expression Contributes to Bladder Cancer Progression
50. Cardiac History and Risk of Post-cystectomy Cardiac Complications
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.